NCT04980690

Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 228 (estimated)
• Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.

Detailed description

The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa). First, the Phase Ia dose escalation will be carried out. After switching to the 3+3 escalation mode, the Phase Ib dose extension study can be carried out at the same time. After Phase Ia is completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.

Conditions

• Advanced Malignant Tumors

Interventions

Type	Name	Description
BIOLOGICAL	IBC0966	IBC0966 is an investigational product.

Timeline

• Start date: 2021-08-31
• Primary completion: 2024-12-01
• Completion: 2025-12-01
• First posted: 2021-07-28
• Last updated: 2023-03-10

Locations

1 site across 1 country: China